In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Innate Pharma SA (IPHYF – Research Report), with a price target of €5.70.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Eric Le Berrigaud’s rating is based on several compelling factors. Firstly, the FDA’s recent granting of Breakthrough Therapy Designation to lacutamab for treating R/R Sezary Syndrome has been a significant positive development. This designation is expected to aid Innate Pharma in finalizing discussions with a potential commercial partner, thereby enhancing the drug’s market potential and commercial viability.
Additionally, the data from the TELLOMAK study supports the approvability of lacutamab, given its favorable safety profile and effectiveness in treating indications with limited therapeutic options. Lacutamab’s demonstrated efficacy, regardless of the KIR3DL2 status, further broadens its target market, offering potential for market expansion. These factors collectively underpin the Buy rating, highlighting the stock’s potential for significant upside.
According to TipRanks, Le Berrigaud is a 3-star analyst with an average return of 7.3% and a 50.82% success rate.